查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1316499

大腸直腸癌藥物市場：按類別、類型和分銷管道 - 2023-2030 年全球預測

Colorectal Cancer Drugs Market by Class, Type, Distribution Channel - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年全球大腸直腸癌藥物市場將達到108.4億美元，年複合成長率為4.96%，大幅成長，預計2030年將達到152.4億美元。

FPNV定位矩陣

FPNV定位矩陣對於評估全球大腸直腸癌治療市場至關重要。透過檢查業務策略和產品滿意度的關鍵指標，我們對供應商進行全面評估，使您能夠根據您的特定需求做出明智的資訊。這種進階分析將供應商分為四個像限，並取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市佔率分析

市場佔有率分析可以深入了解供應商在特定市場領域的當前地位。比較供應商對總收入、基本客群和其他關鍵指標的貢獻，可以幫助公司更好地了解他們在爭奪市場佔有率時的表現以及面臨的情況。該分析還揭示了特定行業的競爭程度、累積和合併的優勢以及研究基準年的合併特徵。

本報告提供了以下幾點見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開發：提供有關利潤豐厚的新興市場的詳細資訊，並分析其在成熟市場的滲透率。

3. 市場多元化：提供有關新產品發布、未開發領域、最新發展和投資的詳細資訊。

4.市場趨勢：全面了解COVID-19、俄羅斯-烏克蘭衝突和高通膨的累積影響。

5.競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、法規狀況、專利狀況、製造能力等進行綜合評估。

6. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告回答了以下問題：

1.全球大腸直腸癌治療藥物市場規模及預測如何？

2.在預測期內，COVID-19對全球大腸直腸癌治療藥物市場的阻礙因素與影響為何？

3.在預測期內，全球大腸直腸癌治療藥物市場需要投資哪些產品/細分市場/應用/領域？

4.你們在全球大腸直腸癌藥物市場的競爭策略是什麼？

5.全球大腸直腸癌藥物市場的技術趨勢和法律規範如何？

6.全球大腸直腸癌治療藥物市場主要廠商的市佔率為何？

7. 哪些型態和策略性措施被認為適合進入全球大腸直腸癌藥物市場？

目錄

第1章 前言

第2章 調查方法

第3章 執行摘要

第4章 市場概況

第5章 市場洞察

  • 市場動態
    • 促進因素
      • 全球結腸癌和直腸癌罹患率飆升
      • 增加抗癌藥物開發的投資和政府資助
      • 提高對先進治療方法的接受度
    • 抑制因素
      • 開發治療結腸癌的藥物非常昂貴
    • 機會
      • 加強大腸直腸癌治療的研究和開發
      • 由於多種環境和遺傳要素，感染人數正在增加。
    • 任務
      • 缺乏高風險大腸直腸癌治療的新輔助/輔助管線藥物的開發
  • 市場趨勢
  • COVID-19 的累積影響
  • 俄羅斯-烏克蘭衝突的累積影響
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法律規範
  • 客戶客製化

第6章 大腸直腸癌治療藥物市場分類

  • 化學處理
    • 5-氟尿嘧啶 (5-FU)
    • 卡培他濱（希羅達）
    • 伊立替康（坎普托沙）
    • 奧沙利鉑（eloxatin）
    • 曲氟尿苷和托吡拉西 (Lonsurf)
  • 免疫療法
    • CTLA-4抑制劑
    • KRAS抑制劑
    • PD-1抑制劑

第7章 大腸直腸癌治療藥物市場：依類型

  • BRAF 或 MEK 抑制劑
  • 表皮生長因子受體抑制劑
  • 免疫調節劑
  • 程序性細胞死亡蛋白1/PD1配體1抑制劑
  • 酪胺酸激酶抑制劑
  • 血管內皮生長因子抑制劑

第8章 大腸直腸癌治療藥物市場：依分銷管道分類

  • 醫院藥房
  • 零售藥房

第9章 北美和南美大腸癌治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章 亞太大結直腸癌治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲大腸直腸癌治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭形勢

  • FPNV定位矩陣
  • 市佔率分析：主要企業
  • 競爭情境分析：主要企業

第13章上市公司名單

第14章附錄

  • 討論指南
  • 關於許可證和定價
Product Code: MRR-431B7BFFBF57

The Global Colorectal Cancer Drugs Market is forecasted to grow significantly, with a projected USD 10.84 billion in 2023 at a CAGR of 4.96% and expected to reach a staggering USD 15.24 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Colorectal Cancer Drugs Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Colorectal Cancer Drugs Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Class, market is studied across Chemotherapy and Immunotherapy. The Chemotherapy is further studied across 5-Fluorouracil (5-FU), Capecitabine (Xeloda), Irinotecan (Camptosar), Oxaliplatin (Eloxatin), and Trifluridine & Tpiracil (Lonsurf). The Immunotherapy is further studied across CTLA-4 Inhibitor, KRAS Inhibitor, and PD-1 Inhibitors. The Chemotherapy is projected to witness significant market share during forecast period.

Based on Type, market is studied across BRAF or MEK Inhibitors, Epidermal Growth Factor Receptor Inhibitors, Immunomodulators, Programmed Cell Death Protein 1/PD1 Ligand 1 Inhibitors, Tyrosine Kinase Inhibitors, and Vascular Endothelial Growth Factor Inhibitors. The Programmed Cell Death Protein 1/PD1 Ligand 1 Inhibitors is projected to witness significant market share during forecast period.

Based on Distribution Channel, market is studied across Hospitals Pharmacies and Retail Pharmacies. The Retail Pharmacies is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Colorectal Cancer Drugs Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Colorectal Cancer Drugs Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Colorectal Cancer Drugs Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Colorectal Cancer Drugs Market?

4. What is the competitive strategic window for opportunities in the Global Colorectal Cancer Drugs Market?

5. What are the technology trends and regulatory frameworks in the Global Colorectal Cancer Drugs Market?

6. What is the market share of the leading vendors in the Global Colorectal Cancer Drugs Market?

7. What modes and strategic moves are considered suitable for entering the Global Colorectal Cancer Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Colorectal Cancer Drugs Market, by Class, 2022 vs 2030
  • 4.3. Colorectal Cancer Drugs Market, by Type, 2022 vs 2030
  • 4.4. Colorectal Cancer Drugs Market, by Distribution Channel, 2022 vs 2030
  • 4.5. Colorectal Cancer Drugs Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Surging prevalence of colon and rectal cancer worldwide
      • 5.1.1.2. Increase in investments and government funding in development of cancer drugs
      • 5.1.1.3. Growing acceptance of advanced therapies
    • 5.1.2. Restraints
      • 5.1.2.1. High cost for developing colon cancer drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing research and development studies for colorectal cancer treatment
      • 5.1.3.2. Growing number of cases due to several environmental and genetic factors
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of development in the neoadjuvant/adjuvant pipeline agents for the treatment of high risk colorectal cancer
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Colorectal Cancer Drugs Market, by Class

  • 6.1. Introduction
  • 6.2. Chemotherapy
    • 6.2.1. 5-Fluorouracil (5-FU)
    • 6.2.2. Capecitabine (Xeloda)
    • 6.2.3. Irinotecan (Camptosar)
    • 6.2.4. Oxaliplatin (Eloxatin)
    • 6.2.5. Trifluridine & Tpiracil (Lonsurf)
  • 6.3. Immunotherapy
    • 6.3.1. CTLA-4 Inhibitor
    • 6.3.2. KRAS Inhibitor
    • 6.3.3. PD-1 Inhibitors

7. Colorectal Cancer Drugs Market, by Type

  • 7.1. Introduction
  • 7.2. BRAF or MEK Inhibitors
  • 7.3. Epidermal Growth Factor Receptor Inhibitors
  • 7.4. Immunomodulators
  • 7.5. Programmed Cell Death Protein 1/PD1 Ligand 1 Inhibitors
  • 7.6. Tyrosine Kinase Inhibitors
  • 7.7. Vascular Endothelial Growth Factor Inhibitors

8. Colorectal Cancer Drugs Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospitals Pharmacies
  • 8.3. Retail Pharmacies

9. Americas Colorectal Cancer Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Colorectal Cancer Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Colorectal Cancer Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. List of Company Mentioned

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. COLORECTAL CANCER DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. COLORECTAL CANCER DRUGS MARKET SIZE, 2022 VS 2030
  • FIGURE 3. COLORECTAL CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2022 VS 2030 (%)
  • FIGURE 5. COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2022 VS 2030 (%)
  • FIGURE 6. COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2030 (%)
  • FIGURE 7. COLORECTAL CANCER DRUGS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 8. COLORECTAL CANCER DRUGS MARKET DYNAMICS
  • FIGURE 9. COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 10. COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 15. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 16. COLORECTAL CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 17. COLORECTAL CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. COLORECTAL CANCER DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. COLORECTAL CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 5. COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 6. COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. COLORECTAL CANCER DRUGS MARKET SIZE, BY 5-FLUOROURACIL (5-FU), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. COLORECTAL CANCER DRUGS MARKET SIZE, BY CAPECITABINE (XELODA), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. COLORECTAL CANCER DRUGS MARKET SIZE, BY IRINOTECAN (CAMPTOSAR), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. COLORECTAL CANCER DRUGS MARKET SIZE, BY OXALIPLATIN (ELOXATIN), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. COLORECTAL CANCER DRUGS MARKET SIZE, BY TRIFLURIDINE & TPIRACIL (LONSURF), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 13. COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. COLORECTAL CANCER DRUGS MARKET SIZE, BY CTLA-4 INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. COLORECTAL CANCER DRUGS MARKET SIZE, BY KRAS INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. COLORECTAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. COLORECTAL CANCER DRUGS MARKET SIZE, BY BRAF OR MEK INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. COLORECTAL CANCER DRUGS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. COLORECTAL CANCER DRUGS MARKET SIZE, BY PROGRAMMED CELL DEATH PROTEIN 1/PD1 LIGAND 1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. COLORECTAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. COLORECTAL CANCER DRUGS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. COLORECTAL CANCER DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. COLORECTAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 236. COLORECTAL CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 237. COLORECTAL CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 238. COLORECTAL CANCER DRUGS MARKET LICENSE & PRICING